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Abstract
Background: Recently, lipid droplets have been found to be involved in an important cytoplasmic organelle for hepatitis C
virus (HCV) production. However, the mechanisms of HCV assembly, budding, and release remain poorly understood.
Retroviruses and some other enveloped viruses require an endosomal sorting complex required for transport (ESCRT)
components and their associated proteins for their budding process.
Methodology/Principal Findings: To determine whether or not the ESCRT system is needed for HCV production, we
examined the infectivity of HCV or the Core levels in culture supernatants as well as HCV RNA levels in HuH-7-derived RSc
cells, in which HCV-JFH1 can infect and efficiently replicate, expressing short hairpin RNA or siRNA targeted to tumor
susceptibility gene 101 (TSG101), apoptosis-linked gene 2 interacting protein X (Alix), Vps4B, charged multivesicular body
protein 4b (CHMP4b), or Brox, all of which are components of the ESCRT system. We found that the infectivity of HCV in the
supernatants was significantly suppressed in these knockdown cells. Consequently, the release of the HCV Core into the
culture supernatants was significantly suppressed in these knockdown cells after HCV-JFH1 infection, while the intracellular
infectivity and the RNA replication of HCV-JFH1 were not significantly affected. Furthermore, the HCV Core mostly
colocalized with CHMP4b, a component of ESCRT-III. In this context, HCV Core could bind to CHMP4b. Nevertheless, we
failed to find the conserved viral late domain motif, which is required for interaction with the ESCRT component, in the HCV-
JFH1 Core, suggesting that HCV Core has a novel motif required for HCV production.
Conclusions/Significance: These results suggest that the ESCRT system is required for infectious HCV production.
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Introduction
Hepatitis C virus (HCV) is a causative agent of chronic
hepatitis, which progresses to liver cirrhosis and hepatocellular
carcinoma. HCV is an enveloped virus with a positive single
stranded 9.6 kb RNA genome, which encodes a large polyprotein
precursor of approximately 3,000 amino acid residues. This
polyprotein is cleaved by a combination of the host and viral
proteases into at least 10 proteins in the following order: Core,
envelope 1 (E1), E2, p7, nonstructural protein 2 (NS2), NS3,
NS4A, NS4B, NS5A, and NS5B [1]. HCV Core, a highly basic
RNA-binding protein, forms a viral capsid and is targeted to lipid
droplets [2–6]. The Core is essential for infectious virion produc-
tion [7]. NS5A, a membrane-associated RNA-binding phospho-
protein, is also involved in the assembly and maturation of
infectious HCV particles [8,9]. Intriguingly, NS5A is a key
regulator of virion production through the phosphorylation by
casein kinase II [9]. Recently, lipid droplets have been found to be
involved in an important cytoplasmic organelle for HCV
production [4]. Indeed, NS5A is known to colocalize with the
Core on lipid droplets [5], and the interaction between NS5A and
the Core is critical for the production of infectious HCV particles
[3]. However, the host factor involved in HCV assembly, budding,
and release remains poorly understood.
Budding is an essential step in the life cycle of enveloped viruses.
Endosomal sorting complex required for transport (ESCRT)
components and associated factors, such as tumor susceptibility gene
101 (TSG101, a component of ESCRT-I), charged multivesicular
body protein 4b (CHMP4b, a component of ESCRT-III), and
apoptosis-linked gene 2 interacting protein X (ALIX,a TSG101- and
CHMP4b-binding protein), have been found to be involved in
membrane remodeling events that accompany endosomal protein
sorting, cytokinesis, and the budding of several enveloped viruses,
such as human immunodeficiency virus type 1 (HIV-1) [10–12]. The
ESCRT complexes I, II, and III are sequentially, or perhaps
concentrically recruited to the endosomal membrane to sequester
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ESCRT-III recruits Vps4 (two isoforms, Vps4A and Vps4B), a
member of the AAA-family of ATPase that disassembles and thereby
terminates and recycles the ESCRT machinery.
Since HCV is also an enveloped RNA virus, we hypothesized
that the ESCRT system might be required for HCV production.
To test this hypothesis, we examined the release of HCV Core into
culture supernatants from cells rendered defective for ESCRT
components by RNA interference. The results provide evidence
that the ESCRT system is required for HCV production.
Materials and Methods
Cell Culture
293FT cells (Invitrogen, Carlsbad, CA) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen)
supplemented with 10% fetal bovine serum (FBS). The HuH-7-
derived cell line, RSc cured cells that cell culture-generated HCV-
JFH1 (JFH1 strain of genotype 2a) [13] could infect and effectively
replicate [14–16] and OR6c and OR6 cells harboring the
genome-length HCV-O RNA with luciferase as a reporter were
cultured in DMEM with 10% FBS as described previously [17,18].
Plasmid Construction
To construct pcDNA3-FLAG-Alix, a DNA fragment encoding
Alix was amplified from total RNAs derived from RSc cells by
RT-PCR using the follwing pairs of primers: Forward 59-CGGG-
ATCCAAGATGGCGACATTCATCTCGGT-39 and reverse 59-
CCGGCGGCCGCTTACTGCTGTGGATAGTAAG-39. The
obtained DNA fragment was subcloned into BamHI-NotIo f
pcDNA3-FLAG vector [19], and the nucleotide sequences were
determined by Big Dye termination cycle sequencing using an ABI
Prism 310 genetic analyzer (Applied Biosystems, Foster City, CA,
USA). The plasmid of pJRN/3-5B was based on pJFH1 [13] and
was constructed as previously described [20].
RNA synthesis, RNA transfection, and Selection of G418-
resistant cells
Plasmid pJRN/3-5B were linearized by XbaI and used for the
RNA synthesis with the T7 MEGAScript kit (Ambion, Austin,
TX). In vitro transcribed RNA was transfected into OR6c cells by
electroporation [17,18]. The transfected cells were selected in
culture medium containing G418 (0.3 mg/ml) for 3 weeks. We
referred to them as OR6c/JRN 3-5B cells.
Immunofluorescence and Confocal Microscopic Analysis
Cells were fixed in 3.6% formaldehyde in phosphate-buffered
saline (PBS) and permeabilized in 0.1% Nonidet P-40 (NP-40) in
PBS at room temperature as previously described [21]. Cells were
incubated with anti-HCV Core antibody (CP-9 and CP-11
mixture; Institute of Immunology, Tokyo, Japan), anti-Myc-Tag
antibody (PL14; Medical & Biological Laboratories, MBL,
Nagoya, Japan), anti-Alix antibody (Covalab, Villeurbanne,
France), and/or anti-FLAG polyclonal antibody (Sigma, St. Louis,
MO) at a 1:300 dilution in PBS containing 3% bovine serum
albumin (BSA) at 37uC for 30 min. Cells were then stained with
fluorescein isothiocyanate (FITC)-conjugated anti-rabbit antibody
(Jackson ImmunoResearch, West Grove, PA) or anti-Cy3-
conjugated anti-mouse antibody (Jackson ImmunoResearch) at a
1:300 dilution in PBS containing BSA at 37uC for 30 min. Lipid
droplets and nuclei were stained with BODIPY 493/503
(Molecular Probes, Invitrogen) and DAPI (49,69-diamidino-2-
phenylindole), respectively. Following extensive washing in PBS,
cells were mounted on slides using a mounting media of 90%
glycerin/10% PBS with 0.01% p-phenylenediamine added to
reduce fading. Samples were viewed under a confocal laser-
scanning microscope (LSM510; Zeiss, Jena, Germany).
RNA Interference
The following siRNAs were used: human TSG101 (siGEN-
OME SMARTpool M-003549-01-0005 and 59-CCUCCAGU-
CUUCUCUCGUCUU-39 sense, 59-GACGAGAGAAGACUG-
GAGGUU-39 antisense), human Alix/PDCD6IP (siGENOME
SMARTpool M-004233-02-0005), human Vps4B (siGENOME
SMARTpool M-013119-02-0005), human CHMP4b (siGEN-
OME SMARTpool M-018075-00-0005), and siGENOME Non-
Targeting siRNA Pool#1 (D-001206-13-05) (Dharmacon,
Thermo Fisher Scientific, Waltham, MA) as a control. siRNAs
(50 nM final concentration) were transiently transfected into either
RSc cells [14–16] or OR6 cells [17,18] using Oligofectamine
(Invitrogen) according to the manufacturer’s instructions. Oligo-
nucleotides with the following sense and antisense sequences were
used for the cloning of short hairpin (sh) RNA-encoding sequences
against TSG101, Alix, Vps4B, or CHMP4b in lentiviral vector:
TSG101i, 59-GATCCCC GGAGGAAATGGATCGTGCCTT-
CAAGAGAGGCACGATCCATTTCCTCCTTTTTGGAAA-39
(sense), 59-AGCTTTTCCAAAAAGGAGGAAATGGATCGTG-
CCTCTCTTGAAGGCACGATCCATTTCCTCCGGG-39 (an-
tisense); Alixi, 59-GATCCCC GGAGGTGTTCCCTGTCTTG-
TTCAAGAGACAAGACAGGGAACACCTCCTTTTTGGAA-
A-39 (sense), 59-AGCTTTTCCAAAAAGGAGGTGTTCCCTG-
TCTTGTCTCTTGAACAAGACAGGGAACACCTCCGGG-39
(antisense); Vps4Bi, 59-GATCCCC GGAGAATCTGATGATC-
CTGTTCAAGAGACAGGATCATCAGATTCTCCTTTTTG-
GAAA-39 (sense), 59-AGCTTTTCCAAAAAGGAGAATCT-
GATGATCCTGTCTCTTGAACAGGATCATCAGATTCTC-
CGGG-39 (antisense); CHMP4bi, 59-GATCCCC GAGGAG-
GACGACGACATGATTCAAGAGATCATGTCGTCGTCC-
TCCTCTTTTTGGAAA-39 (sense), 59-AGCTTTTCCAAAAA-
GAGGAGGACGACGACATGATCTCTTGAATCATGTCG-
TCGTCCTCCTCGGG-39 (antisense); Broxi, 59-GATCCCCG-
GATGACAGTACTAAACCCTTCAAGAGAGGGTTTAGTA-
CTGTCATCCTTTTTGGAAA-39 (sense), 59-AGCTTTTC-
CAAAAAGGATGACAGTACTAAACCCTCTCTTGAAGGG-
TTTAGTACTGTCATCCGGG-39 (antisense). The oligonucleo-
tides above were annealed and subcloned into the BglII-HindIII
site, downstream from an RNA polymerase III promoter of
pSUPER [22], to generate pSUPER-TSG101i, pSUPER-Alixi,
pSUPER-Vps4Bi, and pSUPER-CHMP4bi, respectively. To
construct pLV-TSG101i, pLV-Alixi, pLV-Vps4Bi, and pLV-
CHMP4bi, the BamHI-SalI fragments of the corresponding
pSUPER plasmids were subcloned into the BamHI-SalI site of
pRDI292 [23], an HIV-1-derived self-inactivating lentiviral vector
containing a puromycin resistant marker allowing for the selection
of transduced cells, respectively.
Lentiviral Vector Production
The vesicular stomatitis virus (VSV)-G-pseudotyped HIV-1-
based vector system has been described previously [24–26]. The
lentiviral vector particles were produced by transient transfection
of the second-generation packaging construct pCMV-DR8.91
[24–26] and the VSV-G-envelope-expressing plasmid pMDG2 as
well as pRDI292 into 293FT cells with FuGene6 (Roche
Diagnostics, Basel, Switzerland).
HCV Infection Experiments
The supernatants was collected from cell culture-generated
HCV-JFH1 [13]-infected RSc cells [14–16] at 5 days post-
ESCRT and HCV Production
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filter (Kurabo, Osaka, Japan) until use. For infection experiments
with HCV-JFH1 virus, RSc cells (1610
5 cells/well) were plated
onto 6-well plates and cultured for 24 hours (hrs). Then, we
infected the cells with 50 ml (equivalent to a multiplicity of
infection [MOI] of 0.1) of inoculum. The culture supernatants
were collected and the levels of HCV Core were determined by
enzyme-linked immunosorbent assay (ELISA) (Mitsubishi Kagaku
Bio-Clinical Laboratories, Tokyo, Japan). Total RNA was isolated
from the infected cellular lysates using RNeasy mini kit (Qiagen,
Hilden, Germany) for quantitative RT-PCR analysis of intracel-
lular HCV RNA. The infectivity of HCV in the culture
supernatants was determined by a focus-forming assay at 48 hrs
post-infection. The HCV infected cells were detected using anti-
HCV Core antibody (CP-9 and CP-11). Intracellular HCV
infectivity was determined by a focus-forming assay at 48 hrs
post-inoculation of lysates by repeated freeze and thaw cycles
(three times).
Quantitative RT-PCR Analysis
The quantitative RT-PCR analysis for HCV RNA was per-
formed by real-time LightCycler PCR (Roche) as described
previously [17,18]. We used the following forward and reverse
primer sets for the real-time LightCycler PCR: TSG101, 59-
ATGGCGGTGTCGGAGAGCCA-39 (forward), 59-AACAGGTT-
TGAGATCTTTGT-39 (reverse); Alix, 59-ATGGCGACATT-
CATCTCGGT-39 (forward), 59-TACTGGGCCTGCTCTTCCC-
C-39 (reverse); Vps4B, 59-ATGTCATCCACTTCGCCCAA-39 (for-
ward), 59-ATACTGCACAGCATGCTGAT-39 (reverse); CHMP4b,
59-ATGTCGGTGTTCGGGAAGCT-39 (forward), 59-ATCTCTT-
CCGTGTCCCGCAG-39 (reverse); Brox, 59-ATGACCCATTGG-
TTTCATAG-39 (forward), 59-CCTGGATGACCTCAAGTCAT-39
(reverse); b-actin, 59-TGACGGGGTCACCCACACTG-39 (forward),
59-AAGCTGTAGCCGCGCTCGGT-39 (reverse); and HCV-JFH1,
59-AGAGCCATAGTGGTCTGCGG-39 (forward), 59-CTTTCG-
CAACCCAACGCTAC-39 (reverse).
MTT Assay
Cells (5610
3 cells/well) were plated onto 96-well plates and
cultured for 24, 48 or 72 hrs, then, subjected to the colorimetric 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromid (MTT)
assay according to the manufacturer’s instructions (Cell prolifer-
ation kit I, Roche). The absorbance was read using a microplate
reader (Multiskan FC, Thermo Fisher Scientific) at 550 nm with a
reference wavelength of 690 nm.
Renilla Luciferase (RL) Assay
OR6 cells (1.5610
4 cells/well) [17,18] were plated onto 24-well
plates and cultured for 24 hrs. The cells were transfected with
siRNAs (50 nM) using Oligofectamine and incubated for 72 hrs,
then, subjected to the RL assay according to the manufacturer’s
instructions (Promega, Madison, WI). A lumat LB9507 luminom-
eter (Berthold, Bad Wildbad, Germany) was used to detect RL
activity.
Western Blot Analysis
Cells (2610
5 cells/well) were plated onto 6-well plates and
cultured for 24 or 48 hrs. Cells were lysed in buffer containing
50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 4 mM EDTA, 1%
NP-40, 0.1% sodium dodecyl sulfate (SDS), 1 mM dithiothreitol
(DTT) and 1 mM phenylmethylsulfonyl fluoride (PMSF). Super-
natants from these lysates were subjected to SDS-polyacrylamide
gel electrophoresis, followed by immunoblot analysis using anti-
TSG101 antibody (BD Transduction Laboratories, San Jose, CA),
anti-Alix antibody, anti-Vps4B antibody (Abnova, Taipei, Taiwan)
(A302-078A; Bethyl Laboratories, Montgomery, TX), anti-
CHMP4B antibody (sc-82557; Santa Cruz Biotechnology, Santa
Cruz, CA), anti-HCV Core antibody, anti-b-actin antibody
(Sigma), anti-Myc-Tag antibody, anti-FLAG antibody (M2;
Sigma), anti-Chk2 antibody (DCS-273; MBL), anti-heat shock
protein (HSP) 70 antibody (BD), Living Colors A.v. monoclonal
antibody (JL-8; Clontech, Mountain View, CA), anti-HCV NS5A
monoclonal antibody (no. 8926; a generous gift from A Takami-
zawa, The Research Foundation for Microbial Diseases of Osaka
University, Japan), or anti-HCV NS5A polyclonal antibody (a
generous gift from K Shimotohno, Chiba Institute of Technology,
Chiba, Japan).
Immunoprecipitation Analysis
Cells were lysed in buffer containing 10 mM Tris-HCl (pH 8.0),
150 mM NaCl, 1% NP-40, 1 mM PMSF, and protease inhibitor
cocktail containing 104 mM 4-(2-aminoethyl)benzenesulfonyl fluo-
ride hydrochloride, 80 nM aprotinin, 2.1 mM leupeptin, 3.6 mM
bestatin, 1.5 mM pepstatin A, and 1.4 mM E-64 (Sigma). Lysates
were pre-cleaned with 30 ml of protein-G-Sepharose (GE Health-
care Bio-Sciences). Pre-cleaned supernatants were incubated with
5 ml of Living Colors A.v. monoclonal antibody or anti-FLAG
antibody at 4uC for 1 hr. Following absorption of the precipitates
on 30 ml of protein-G-Sepharose resin for 1 hr, the resin was
washed four times with 700 ml lysis buffer. Proteins were eluted by
boiling the resin for 5 min in 16 Laemmli sample buffer. The
proteins were then subjected to SDS-PAGE, followed by
immunoblotting analysis using either anti-FLAG antibody, Living
Colors A.v. monoclonal antibody or anti-HCV Core antibody.
Statistical Analysis
Statistical comparison of the infectivity of HCV in the culture
supernatants between the knockdown cells and the control cells
was performed using the Student’s t-test. P values of less than 0.05
were considered statistically significant. All error bars indicate
standard deviation.
Results
The ESCRT system is required for HCV production
To investigate the potential role(s) of the ESCRT system in the
HCV life cycle, we first used lentiviral vector-mediated RNA
interference to stably knockdown the ESCRT components,
including TSG101, Alix, Vps4B, or CHMP4b in HuH-7-derived
RSc cured cells that cell-culture-generated HCVcc (HCV-JFH1,
genotype 2a) [13] could infect and effectively replicate [14–16]. We
used puromycin-resistant pooled cells 10 days after the lentiviral
transduction in all experiments. Western blot and real-time
LightCycler RT-PCR analyses for TSG101, Alix, Vps4B, or
CHMP4b demonstrated a very effective knockdown of each
ESCRT component in RSc cells transduced with lentiviral vectors
expressing the corresponding shRNAs (Fig. 1A–E). Importantly, we
noticed that the depletion of ESCRT components did not affect the
levels of several cellular proteins, including HSP70, Chk2, and b-
actin (Fig.1A). To test thecell toxicityofeachshRNA,weexamined
colorimetric MTT assay. In this context, we demonstrated that the
shRNAs did not affect the cell viabilities (Fig. 1F). We next
examined the levels of HCV Core and the infectivity of HCV in the
culture supernatants as well as the level of HCV RNA in the
TSG101, Alix, Vps4B, or CHMP4b stable knockdown RSc cells
97 h after HCV-JFH1 infection at an MOI of 0.1. The results
showed that the release of HCV Core into the culture supernatants
ESCRT and HCV Production
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e14517Figure 1. ESCRT components are required for the infectious HCV production. (A) Inhibition of TSG101, Alix, Vps4B, or CHMP4b protein
expression by shRNA-producing lentiviral vectors. The results of the Western blot analysis of cellular lysates with anti-TSG101, anti-Alix, anti-Vps4B, anti-
CHMP4b, anti-Chk2, anti-HSP70, or anti-b-actin antibody in RSc cells expressing shRNA targeted to TSG101 (TSG101i), Alix (Alixi), Vps4B (Vps4Bi), or CHMP4b
( C H M P 4 b i )a sw e l la si nR S cc e l l st r a n s d u c e dw i t hac o n t r o ll e n t i v i r a lv e c t o r (Con) are shown. Real-time LightCycler RT-PCR for TSG101 (B), Alix (C), Vps4B (D), or
CHMP4b mRNA (E) was performed as well as for b-actin mRNA in triplicate. Each mRNA level was calculated relative to the level in RSc cells transduced with a
control lentiviral vector (Con) which was assigned as 100%. Error bars in this panel and other figures indicate standard deviations. (F) MTT assay of each
knockdown RSc cells at the indicated time. (G) The levels of HCV Core in the culture supernatants from the stable knockdown RSc cells 97 h after inoculation of
HCV-JFH1 at an MOI of 0.1 were determined by ELISA. Experiments were done in triplicate and columns represent the mean Core protein levels. (H) The
infectivity of HCV in the culture supernatants from the stable knockdown RSc cells 97 hrs after inoculation of HCV-JFH1 at an MOI of 0.1 was determined bya
focus-forming assay at 48 hrs post-infection. Experiments were done in triplicate and each virus titer was calculated relative to the level in RSc cells transduced
with a control lentiviral vector (Con) which was assigned as 100%. Asterisks indicate significant differences compared to the control treatment. *P,0.05;
**P,0.01. (I)The level of intracellular genome-length HCV-JFH1 RNA inthe cellsat 97 hrs post-infectionwas monitored byreal-time LightCycler RT-PCR. Results
ESCRT and HCV Production
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JFH1 infection (Fig. 1G). Importantly, the infectivity of HCV in the
culture supernatants was also significantly suppressed in these
knockdown cells (Fig. 1H), while the RNA replication of HCV-
JFH1 was not affected in the TSG101 or Alix knockdown cells and
was somewhat decreased in the Vps4B and CHMP4b knockdown
cells (Fig. 1I). This suggested that the ESCRT system is associated
withinfectiousHCVproduction.To further confirm whetherornot
theESCRTsystemis involved inHCVproduction,we analyzedthe
single-round HCV replication. For this, we used RSc cells
transiently transfected with a pool of siRNAs specific for TSG101,
Alix, Vps4B, or CHMP4b as well as a pool of control siRNAs (Con)
following HCV infection. In spite of very effective knockdown of
each ESCRT component (Fig. 1J), we demonstrated that the
siRNAs did not affect the cell viabilities by MTT assay (Fig. 1K).
Consistent with our finding using the stable knockdown cells, we
observed that the release of HCV Core or the infectivity of HCV
into the culture supernatants was significantly suppressed in these
transientknockdowncells24 hrsafterHCV-JFH1 infection(Fig.1L
and 1M). Furthermore, weexamined theeffectof siRNAspecificfor
TSG101,Alix,Vps4B,orCHMP4binHCVRNAreplicationusing
the subgenomic JFH1 replicon, JRN/3-5B, encoding Renilla
luciferase gene for monitoring the HCV RNA replication in
HuH-7-derived OR6c JRN/3-5B cells (Fig. 2A and 2B) or an OR6
assay system, which was developed as a luciferase reporter assay
system for monitoring genome-length HCV RNA replication
(HCV-O, genotype 1b) in HuH-7-derived OR6 cells (Fig. 2C)
[17,18]. The results showed that these siRNAs could not affect
HCV RNA replication as well as the levels of intracellular NS5A
proteins (Fig. 2A–C). Although we have demonstrated that the
ESCRT system is required for production of extracellular infectious
HCV particles, it is not clear whether or not these findings are
associated with the assembly of intracellular infectious particles. To
test this point, infectivity of intracellular infectious particles was
analyzed following lysis of HCV-JFH1-infected knockdown cells by
repetitive freeze and thaw. Consequently, we did not observe any
significant effects of siRNAs on the accumulation of intracellular
infectious HCV-JFH1, while the accumulation of extracellular
HCV was significantly suppressed in these knockdown cells (Fig. 2D
and 2E), indicating that inhibition of the ESCRT system does not
block the accumulation of intracellular infectious HCV particles.
Furthermore, Western blot analysis of cell lysates demonstrated that
the level of intracellular HCV Core and NS5A was not affected in
these knockdown cells 72 hrs post-infection (Fig. 2F). Thus, we
conclude that the ESCRT system is not required for the assembly of
infectious particlesbuttheESCRT system is required for late step of
HCV production.
HCV Core can target into lipid droplets in the ESCRT
knockdown cells
Since lipid droplets have been shown to be involved in an
important cytoplasmic organelle for HCV production [4], we
performed immunofluorescence and confocal microscopic analy-
ses to determine whether or not HCV Core misses localization
into lipid droplets in the ESCRT knockdown cells. We found that
the Core was targeted into lipid droplets even in TSG101
knockdown, Alix knockdown, Vps4B knockdown, or CHMP4b
knockdown RSc cells as well as in the control RSc cells after HCV
infection (Fig. 3). This suggests that the ESCRT system plays a role
in the late step after the Core is targeted into lipid droplets in the
HCV life cycle.
HCV Core interacts with CHMP4b
To determine whether or not HCV Core can interact with
ESCRT component(s), we examined their subcellular localization
by confocal laser scanning microscopy. Consequently, the Core
mostly colocalized with CHMP4b-green fluorescent protein (GFP)
or FLAG-tagged CHMP4b in the perinuclear region of 293FT
cells coexpressing them (Fig. 4A and 4B), while the CHMP4b-GFP
alone was slightly diffused in the cytoplasm (Fig. 4A), indicating
the recruitment of CHMP4b in the Core-expressing area.
Importantly, we observed similar partial colocalization in HCV-
JFH1-infected RSc cells expressing CHMP4b-GFP (Fig. 4C),
whereas the CHMP4b-GFP alone was diffused in the cytoplasm in
the uninfected RSc cells (Fig. 4C), suggesting the interaction of
HCV Core with CHMP4b. Unfortunately, we failed to observe
endogenous CHMP4b using several commercially available anti-
CHMP4b antibody (data not shown). Consistent with a previous
report that interaction between HCV Core and NS5A is critical
for HCV production [3], we found the partial colocalization of
NS5A with CHMP4b-GFP as well as the colocalization of Core
with CHMP4b-GFP in HCV-JFH1-infected RSc cells (Fig. 4C).
Then, we examined whether or not HCV Core can bind to
CHMP4b by immunoprecipitation analysis. 293FT cells trans-
fected with 4 mg of pCHMP4b-GFP, pEGFP C3 (Clontech),
pcDNA3-FLAG [19], pcDNA3-FLAG-Alix or pFLAG-CHMP4b
and RSc cells 5 days after inoculation of HCV-JFH1 at an MOI of
4 were lysed and performed immunoprecipitation of lysate
mixtures of HCV-JFH1-infected RSc cells and 293FT cells
expressing CHMP4b-GFP, GFP alone, FLAG-CHMP4b or
FLAG-epitope alone with anti-FLAG or anti-GFP antibody.
Consequently, we observed that the Core but not the NS5A
could bind to FLAG-CHMP4b (Fig. 4D). However, the Core was
not immunoprecipitated with anti-FLAG antibody using the lysate
mixtures of HCV-JFH1-infected RSc cell lysates and 293FT cells
expressing FLAG-epitope alone or FLAG-Alix (Fig. 4D). Further-
more, the Core was coimmunoprecipitated with CHMP4b-GFP
but not GFP when lysate mixtures of HCV-JFH1-infected RSc
cells and 293FT cells expressing CHMP4b-GFP or GFP alone
were used (Fig. 4D). In contrast, we failed to observe the marked
colocalization of HCV-JFH1 Core with Myc-tagged TSG101 in
HCV-JFH1-infected RSc cells expressing Myc-TSG101 or
endogenous Alix in HCV-JFH1-infected RSc cells (Fig. 5A). Thus,
we concluded that the HCV Core was associated with CHMP4b.
from three independent experiments are shown. (J) Inhibition of TSG101, Alix, Vps4B, or CHMP4b protein expression by 72 hrs after transient transfection of
RSc cells with a pool of control siRNA (Con) or a pool of siRNA specific for Alix, Vps4B, or CHMP4b (50 nM). The results of the Western blot analysis of cellular
lysateswith anti-TSG101, anti-Alix, anti-Vps4B, anti-CHMP4b, or anti-b-actin antibody isshown. (K) MTT assay of each knockdownRSc cells at the indicated time.
(L) The levels of HCV Core in the culture supernatants were determined by ELISA 24 hrs after inoculation of HCV-JFH1. RSc cells were transiently transfected
with a pool of control siRNA (Con) or a pool of siRNA specific for TSG101, Alix, Vps4B, or CHMP4b (50 nM). At 48 hrs after transfection, the cells were inoculated
with HCV-JFH1 at an MOI of 5 and incubated for 2 hrs. Then, culture medium was changed and incubated for 22 hrs. Experiments were done in triplicate and
each Core level was calculated relative to the level in the culture supernatants from the control cells and indicated below.
(M) The infectivity of HCV in the culture supernatants from the transient knockdown RSc cells 24 hrs after inoculation of HCV-JFH1 at an MOI of 5 was
determined by a focus-forming assay at 48 hrs post-infection. Experiments were done in triplicate and each virus titer was calculated relative to the level in RSc
cells transfected with a control siRNA (Con) which was assigned as 100%. Asterisks indicate significant differences compared to the control treatment. *P,0.05;
**P,0.01.
doi:10.1371/journal.pone.0014517.g001
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and Brox, a novel farnesylated Bro1 domain-containing protein,
since Brox was recently identified as a CHMP4-binding protein
[27]. In this context, the Core partially colocalized with GFP-Brox
in 293FT cells coexpressing of HCV Core and GFP-Brox (Fig. 5B).
Importantly, we observed similar partial colocalization in HCV-
JFH1-infected RSc cells expressing GFP-Brox (Fig. 5C). On the
other hand, the CHMP4b-GFP alone was diffused in the
cytoplasm of uninfected RSc cells (Fig. 5C). To examine the
potential role of Brox in HCV life cycle, we established the Brox
knockdown RSc cells by lentiviral vector expressing shRNA
targeted to Brox (Fig. 5D). Consequently, we found that the release
of HCV Core or the infectivity of HCV into the culture
supernatants was significantly suppressed in the Brox knockdown
cells 4 days after HCV-JFH1 infection (Fig. 5E and 5F), while the
RNA replication of HCV-JFH1 was marginally affected in the
knockdown cells (Fig. 5G) in spite of the very effective knockdown
of Brox mRNA (Fig. 5D), suggesting that Brox is also required for
the infectious HCV production.
Discussion
In this study, we have demonstrated that the ESCRT system is
required for infectious HCV production, and that HCV Core but
not NS5A binds to CHMP4b, a component of ESCRT-III.
Although RNA replication of HCV-JFH1 was not affected in the
TSG101 knockdown or the Alix knockdown cells, the infectivity of
HCV in the culture supernatants was significantly suppressed in
these knockdown cells after HCV-JFH1 infection (Fig. 1G and
1H). Furthermore, siRNA targeted to TSG101, Alix, Vps4B, or
CHMP4b significantly suppressed HCV Core level or the
infectivity of HCV in the culture supernatants (Fig. 1L, 1M, and
Figure 2. ESCRT system is not required for HCV RNA replication and assembly of intracellular infectious HCV. (A) Schematic gene
organization of subgenomic JFH1 (JRN/3-5B) RNA encoding Renilla luciferase gene. Renilla luciferase gene (RLuc) is depicted as a box and is
expressed as a fusion protein with Neo. The HCV RNA replication level in each ESCRT knockdown OR6c JRN/3-5B cells by lentiviral vector-mediated
RNA interference (shRNA) was monitored by RL assay. The RL activity (RLU) is shown. The results shown are means from three independent
experiments. (B) 72 hrs after the transfection of OR6c JRN/3-5B polyclonal cells with each of the siRNA (50 nM), the HCV RNA replication level was
monitored by RL assay as described in (A). (C) Schematic gene organization of genome-length HCV-O RNA encoding Renilla luciferase gene. The
position of an adaptive mutation, K1609E, is indicated by a triangle. 72 hrs after the transfection of OR6 cells with each of the siRNA (50 nM), the HCV
RNA replication level was monitored by RL assay as described in (A). (D) The infectivity of HCV in the culture supernatants from the transient
knockdown RSc cells 24 hrs after inoculation of HCV-JFH1 at an MOI of 2 was determined by a focus-forming assay at 48 hrs post-infection.
Experiments were done in triplicate and each virus titer was calculated relative to the level in RSc cells transfected with a control siRNA (Con) which
was assigned as 100%. (E) Intracellular HCV infectivity was determined by a focus-forming assay at 48 hrs post-inoculation of lysates by repeated
freeze and thaw cycles as described in (D). (F) RSc cells were transiently transfected with a pool of control siRNA (Con) or a pool of siRNA specific for
Alix, Vps4B, or CHMP4b (50 nM). At 24 hrs after the transfection, the cells were inoculated with HCV-JFH1 at an MOI of 0.2 and incubated for 48 hrs.
Then, culture medium was changed and incubated for 24 hours. Western blotting of cell lysates 72 hrs post-infection with anti-b-actin, anti-HCV
NS5A, or anti-HCV Core antibody is shown.
doi:10.1371/journal.pone.0014517.g002
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(Fig. 2E and 2F). Accordingly, we noticed some discrepancy that
shRNA targeted to Vps4B or CHMP4b somewhat decreased
intracellular HCV RNA replication (Fig. 1I), whereas siRNA
targeted to TASG101, Alix, Vps4B or CHMP4b did not affect the
RNA replication of subgenomic replicon of JFH1 (Fig. 2A and 2B).
Furthermore, siRNAs targeted to TSG101, Alix, Vps4B, or
CHMP4b did not affect HCV-O (genotype 1b) RNA replication
using the OR6 assay system [17,18] (Fig. 2C), indicating that the
ESCRT system is unrelated to the HCV RNA replication of
genotype 1b. Thus, we suggested that the ESCRT system is not
significant for HCV RNA replication. Within the family
Flaviviridae, NS3 of the Japanese encephalitis virus (JEV) is also
known to interact with TSG101 and microtubules, suggesting their
potential roles in JEV assembly [28]. Accordingly, HCV NS3 has
been involved in HCV particle assembly and infectivity [29,30].
However, whether HCV NS3 or another HCV protein binds to
TSG101 remains to be investigated. At least, we did not observe
the interaction between HCV NS5A and CHMP4b (Fig. 4D), Alix
(Fig. 4D), TSG101, or Vps4B (data not shown).
Efficient enveloped virus release requires cis-acting viral late
domains (L-domains), including P(T/S)AP, YPXnL (where X is
any amino acid), and PPXY amino acid L-domain motif that are
found in the structural proteins of other enveloped viruses [10,11].
Unlike the case with these enveloped viruses, we failed to find the
three types of conserved viral L-domain motif in the HCV-JFH1
Core (data not shown). Nevertheless, we observed that the Core
bound to CHMP4b, whereas NS5A did not (Fig. 4D), suggesting
that the Core has a novel motif required for the HCV production.
In this regard, Blanchard et al. reported that the aspartic acid at
position 111 in the Core is crucial for virus assembly [31].
Interestingly, the conversion of the aspartic acid into alanine at
amino acid 111 (PTDP to PTAP), which creates the PTAP L-
domain motif, enhanced the release of HCV Core in the cell
culture medium (a 2.5-fold increase) compared with the wild-type
Core [31]. In contrast, Klein et al. demonstrated that the D111A
mutation in the Core had no effect on HCV capsid assembly [32].
Furthermore, Murray et al found that serine 99, a putative
phosphorylation site, in the Core was essential for infectious virion
production [7]. In any event, the Core motif that is needed for
interaction with the ESCRT components remains to be identified.
Ubiquitin modification of viral protein has been implicated in
virion egress as well as in protein turnover. Indeed, the ubiquitin/
proteasome system is required for the retrovirus budding
machinery, since proteasome inhibition interferes with retroviral
Gag polyprotein processing, release, and maturation. The
ubiquitin modification of the HIV-1 p6 domain of Gag enhances
TSG101 binding [12]. In the case of HCV Core, proteasomal
degradation of the Core is mediated by two distinct mechanisms
[33–36]. E6AP E3 ubiquitin ligase mediates ubiquitylation and
degradation of the Core [34]. In contrast, proteasome activator
PA28c (11S regulator c), an HCV Core-binding protein, is
involved in the ubiquitin-independent degradation of the Core
and HCV propagation [33,35,36]. However, little is known
whether or not the ubiquitin modification of the Core might be
involved in HCV egress like other enveloped viruses.
Finally, the identification of the site of viral particle assembly
and budding is an intriguing issue. In case of HCV, at present, it is
very difficult to visualize the HCV budding site in the infected cells
by an electron microscopy. However, recent studies suggested that
lipid droplets are an important cytoplasmic organelle for HCV
production [4]. In this regard, Shavinskaya et al. demonstrated that
Figure 3. HCV Core is targeted to lipid droplets even in the ESCRT knockdown cells. TheRSccellstransducedwitha controllentiviral vector
(Con), the TSG101 knockdown (TSG101i), the Alix knockdown (Alixi), the Vps4B knockdown (Vps4Bi), or the CHMP4b knockdown (CHMP4bi) cells were
infected with HCV-JFH1. Cells were fixed 60 hrs post-infection and were then examined by confocal laser scanning microscopy. Cells were stained with
anti-HCV Core (CP-9 and CP-11 mixture) and were then visualized with Cy3 (red). Lipid droplets and nuclei were stained with BODIPY 493/503 (green)
and DAPI (blue), respectively. Images were visualized using confocal laser scanning microscopy. Colocalization is shown in yellow (Merged).
doi:10.1371/journal.pone.0014517.g003
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PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e14517Figure 4. HCV Core interacts with CHMP4b. (A–C) HCV Core colocalizes with CHMP4b. 293FT cells cotransfected with 100 ng of pcDNA3/core (JFH1)
and either 100 ng of pCHMP4b-GFP [39] (A) or pFLAG-CHMP4b [39] (B) were examined by confocal laser scanning microscopy. Cells were stained with anti-
HCV Core and anti-FLAG polyclonal antibody and were then visualized with FITC (FLAG-CHMP4b) or Cy3 (Core). Images were visualized using confocal laser
scanning microscopy. The right panels exhibit the two-color overlay images (Merged). Colocalization is shown in yellow. (C) The Core or NS5A partially
colocalizes with CHMP4b in HCV-JFH1-infected RSc cells. RSc cells transfected with 100 ng of pCHMP4b-GFP were infected with HCV-JFH1. Cells were fixed
60 hrs post-infection and were then examined by confocal laser scanning microscopy as shown in panel (A). (D) HCV Core binds to CHMP4b. 293FT cells
transfected with 4 mg of pCHMP4b-GFP, pEGFP C3 (Clontech), pcDNA3-FLAG, pcDNA3-FLAG-Alix or pFLAG-CHMP4b and RSc cells 5 days after inoculation of
HCV-JFH1 at an MOI of 4 were lysed. The mixtures of these lysates were immunoprecipitated with either anti-FLAG or Living Colors A.v. monoclonal antibody
(anti-GFP antibody), followed by immunoblot analysis using anti-HCV Core, anti-HCV NS5A, anti-FLAG, and/or Living Colors A.v. monoclonal antibody.
doi:10.1371/journal.pone.0014517.g004
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determinant for efficient virus assembly [6]. The HCV Core
induces lipid droplet redistribution in a microtubule- and dynein-
dependent manner, since disrupting the microtubule network
reduced the HCV titer, implicating transport networks in virus
assembly and release [2]. Furthermore, Sandrin et al. reported that
HCV envelope proteins localized to ESCRT-associated multive-
sicular body (MVB) [37]. Quite recently, Corless et al. have
demonstrated that Vps4B and the ESCRT-III complex are
required for HCV production [38]. Consistent with our findings,
their dominant-negative forms of Vps4B and CHMP4B clearly
suppressed HCV production. However, their dominant-negative
forms of TSG101 and Alix failed to suppress the HCV production
and they suggested that both TSG101 and Alix are unrelated to
the HCV production. In contrast, we have demonstrated both
TSG101 and Alix are also required for the infectious HCV
Figure 5. Brox is required for HCV life cycle. (A) Subcellular localization of Myc-tagged TSG101 in HCV-JFH1-infected RSc cells. RSc cells
transfected with 100 ng of pBj-Myc-TSG101 [40] were infected with HCV-JFH1. Cells were fixed 60 hrs post-infection and were then examined by
confocal laser scanning microscopy as shown in Fig. 3. High magnification image of area 1 is shown. Subcellular localization of endogenous Alix in
HCV-JFH1-infected RSc cells 60 hrs post-infection. Cells were stained with anti-Alix and anti-HCV Core antibodies and were examined by confocal
laser scanning microscopy. High magnification images of area 1 and area 2 are shown. (B) HCV Core partially colocalizes with Brox. 293FT cells
cotransfected with 100 ng of pcDNA3/core (JFH1) and 100 ng of pmGFP-Brox
WT [27] were examined by confocal laser scanning microscopy. (C) The
HCV Core partially colocalizes with Brox in HCV-JFH1-infected RSc cells. RSc cells transfected with 100 ng of pmGFP-Brox
WT were infected with HCV-
JFH1. Cells were fixed 60 hrs post-infection and were then examined by confocal laser scanning microscopy. (D) Inhibition of Brox mRNA expression
by the shRNA-producing lentiviral vector. Real-time LightCycler RT-PCR for Brox was performed as well as for b-actin mRNA in triplicate. Each mRNA
level was calculated relative to the level in RSc cells transduced with a control lentiviral vector (Con) which was assigned as 100%. (E) The levels of
HCV Core in the culture supernatants from the Brox knockdown RSc cells (Broxi) 72 hrs after inoculation of HCV-JFH1 were determined by ELISA.
(F) The infectivity of HCV in the culture supernatants was determined by a focus-forming assay at 48 hrs post-infection. Experiments were done in
triplicate and each virus titer was calculated relative to the level in RSc cells transduced with a control lentiviral vector (Con) which was assigned as
100%. Asterisks indicate significant differences compared to the control treatment. *P,0.05; **P,0.01. (G) The levels of intracellular genome-length
HCV-JFH1 RNA in the cells used in (E) were monitored by real-time LightCycler RT-PCR.
doi:10.1371/journal.pone.0014517.g005
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explain such discrepancy due to the difference of the methodology
in our study utilized shRNAs and siRNAs instead of dominant-
negative forms of TSG101 and Alix. Importantly, they demon-
strated that the dominant-negative forms of Vps4B and CHMP4b
did not affect the HCV RNA replication and the accumulation of
intracellular infectious particles, suggesting that Vps4B and
CHMP4b are unrelated to HCV RNA replication. Indeed, we
have demonstrated that the ESCRT system is not required for the
assembly of intracellular infectious HCV particles (Fig. 2E).
Notably, we have demonstrated for the first time that HCV Core
associated with CHMP4b (Fig. 4). Accordingly, we have also
demonstrated that Brox, a CHMP4b binding protein, is required
for HCV production (Fig. 5D–G). Taking together the past and
present findings, we propose that the ESCRT system is involved in
infectious HCV production after the HCV assembly that occurs
on lipid droplets.
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